Company intelligence / Profile preview

Biotech Equity Partners

Ownership: Private
Development stage: Other

Overview

The primary objective of the Phase I study was to determine safety and tolerability of FP253, a gene-directed enzyme prodrug system designed to localize chemotherapy activation within the prostate. No published results are available; current clinical status is unknown.

Therapeutic areas: Oncology
Modalities: Gene therapyViral vector-based therapyEnzyme replacement therapy (via gene-directed enzyme prodrug therapy, GDEPT)
Industry: Biotech

Drug pipeline

1 asset

FP253

Beyond the preview

Go deeper on Biotech Equity Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotech Equity Partners.

Explore the full profile